RxDoctor Payments Data

David Meriwether, MD

Urology · Summersville, WVNPI 1083600191

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,674 of the $2,235 with a category attached, or 74.9%. 11 manufacturers reported payments, led by Astellas Pharma US Inc at 57.9% of the total. Reporting peaked in 2021 at $717 and has fallen 73.5% since, to $190 in 2024. That places this record below the midpoint for urology clinicians in WV, where the typical reported total is $2,534.

$2,235in general payments, 2019–2025

Across 114 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Pfizer$339
  • Bayer$214
  • Merck$147
  • Urovant Sciences Inc$102
  • Blue Earth Diagnostics$31
  • plus $108 from 5 others

What the payments were for

  • Food & beverage$1,67475%
  • Education$56125%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,235 in reported general payments places this provider in the 40th percentile of 67 urology providers in West Virginia.

See all urology providers in West Virginia

Medicare billing

Part B allowed, 2024
$32,323
Medicare patients
157
Services billed
632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide78$1,153,301
MyrbetriqMirabegron125$119,371
ElmironPentosan Polysulfate Sodium20$27,990
Trimethoprim320$18,474
PremarinEstrogens, Conjugated18$9,168
Tamsulosin Hcl595$7,091
Finasteride322$4,453
NitrofurantoinNitrofurantoin Macrocrystal105$3,899
Oxybutynin Chloride ErOxybutynin Chloride185$1,677
Dutasteride54$1,274
Potassium Citrate ErPotassium Citrate11$1,175
Estradiol21$702
Ciprofloxacin Hcl58$299
Doxazosin Mesylate22$186
Terazosin Hcl11$127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,293$1,272,671203 claims
PfizerPremarin$339$9,16818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 67 urology providers in West Virginia.

Other urology in Summersville

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →